Next |
home / stock / asln / asln message board
Subject | By | Source | When |
---|---|---|---|
$ASLN Good read | ClayTrader | investorshub | 07/03/2023 4:51:52 PM |
$ASLN bulls and bears | keekee | investorshub | 07/03/2023 5:08:15 AM |
$ASLN should we be shorting? | keekee | investorshub | 07/03/2023 12:14:05 AM |
Price trading up | senderos | investorshub | 07/02/2023 8:31:34 PM |
The now last up | ALERTS100%to10000%GAIN | investorshub | 06/30/2023 6:45:53 AM |
where is the squeeze? | wesley_ | investorshub | 06/28/2023 12:39:10 AM |
short squeeze article | keekee | investorshub | 06/27/2023 7:14:26 PM |
$ASLN Do we have a winner?Turn around time? | Canna_Business | investorshub | 06/23/2023 11:45:03 AM |
Volume | Awl416 | investorshub | 06/22/2023 11:46:51 AM |
short squeeze all day | starbuxsux | investorshub | 06/21/2023 11:10:37 AM |
$ASLN Time for this to show some returns | keekee | investorshub | 06/21/2023 10:06:49 AM |
$ASLN Price now | sick nam vet | investorshub | 06/20/2023 9:16:34 PM |
$ASLN The gaining | senderos | investorshub | 06/17/2023 8:31:59 AM |
$ASLN The now | keekee | investorshub | 06/17/2023 6:07:45 AM |
must see | jimmy lipper | investorshub | 06/16/2023 10:40:49 PM |
$ASLN Price trading up | keekee | investorshub | 06/16/2023 3:49:46 PM |
$ASLN bulls and bears | iluvkush | investorshub | 06/14/2023 10:24:27 PM |
$ASLN we got news | bcnuby1 | investorshub | 06/14/2023 7:04:38 AM |
Price now | starbuxsux | investorshub | 06/14/2023 12:35:47 AM |
Price trading | ClayTrader | investorshub | 06/13/2023 9:21:00 PM |
News, Short Squeeze, Breakout and More Instantly...
ASLAN Pharmaceuticals Limited Company Name:
ASLN Stock Symbol:
NASDAQ Market:
SAN MATEO, Calif. and SINGAPORE, April 19, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it received a letter (the “Lett...
In a preliminary review of blinded data from the ongoing TREK-DX study, 45% (10/22) of patients achieved at least a 90% reduction in their EASI score (EASI-90) after 16 weeks. 56% (5/9) of patients with prior inadequate response to dupilumab achieved EASI-90 and 56% (5/9) of patients ...